| 名稱 | R406 |
| 描述 | R406 (R-406 besylate) is an effective Syk inhibitor (IC50: 41 nM) and shows no effects on Lyn. |
| 細胞實驗 | Human primary macrophages were derived from CD14 peripheral blood mononuclear cell according to the protocol specified in the monocyte isolation kit and by subsequently expanding the monocytes in 100 ng/ml human GM-CSF for 5 days to drive differentiation to macrophages. THP-1 cells were primed with 10 ng/ml IFN-γ for 6 days before stimulation. Monocyte-derived macrophages were stimulated by immobilized (plate-bound) human IgG. R406 and 15,000 cells were added to the IgG-coated wells and incubated for 16 to 20 h at 37°C. LPS was used at a final concentration of 10 ng/ml in uncoated wells. TNF concentration in the supernatants was measured by Luminex assay [1]. |
| 激酶實驗 | The fluorescence polarization reactions were performed as described elsewhere. For Ki determination, duplicate 200-μl reactions were set up at eight different ATP concentrations from 200 μM (2-fold serial dilutions) in the presence of either DMSO or R406 at 125, 62.5, 31.25, 15.5, or 7.8 nM. At different time points, 20 μl of each reaction was removed and quenched to stop the reaction. For each concentration of R406, the rate of reaction at each concentration of ATP was determined and plotted against the ATP concentration to determine the apparent Km and Vmax (maximal rate). Finally, the apparent Km (or apparent Km/Vmax) was plotted against the inhibitor concentration to determine the Ki. All data analysis was performed using Prism and Prism enzyme kinetics programs [1]. |
| 動物實驗 | Mice were challenged intravenously with 1% ovalbumin (OVA) in saline (10 mg/kg) containing 1% Evans blue dye. Ten minutes later, mice were anesthetized with isofluorane and shaved dorsolaterally. The rabbit anti-OVA IgG (50 μg/25 μl) was injected intradermally on the left side of the back at three adjacent locations. Three injections of rabbit polyclonal IgG (50 μg/25 μl) on the opposite side of the same animal served as controls. R406 or vehicle (67% PEG 400) was administered to animals 60 min before antibody/antigen challenge. Four hours after challenge, the animals were euthanized, and skin tissue was assessed for edema and inflammation by measuring dye extravasation into the surrounding tissue. Punch biopsy of the injection sites (8 mm) were incubated in 2 ml of formamide at 80°C overnight. The concentration of the extravasated Evans blue dye was measured spectrophotometrically at OD610 [1]. |
| 體外活性 | R406 dose-dependently inhibited anti-IgE-mediated CHMC degranulation measured as tryptase release (EC50: 0.056 μM) but showed no activity on ionomycin-triggered tryptase release. R406 also inhibited the anti-IgE induced production and release of LTC4 and cytokines and chemokines, including TNF, IL-8, and GM-CSF. R406 potently inhibited Syk kinase activity in vitro with an IC50 of 41 nM. Subsequent enzyme kinetic studies showed R406 to be a competitive inhibitor for ATP binding with a Ki of 30 nM [1]. R406 induces apoptosis and cell cycle arrest while decreasing downstream phosphatidylinositol-3'-kinase (PI3K)/Akt signaling in EBV+ B cell lymphoma PTLD lines in vitro [2]. The prosurvival effects promoted by anti-IgM stimulation and nurselike cells were abrogated by R406. BCR triggering up-regulated adhesion molecules and increased CLL cell migration toward the chemokines CXCL12 and CXCL13. BCR activation also enhanced CLL cell migration beneath marrow stromal cells. These responses were blocked by R406, which furthermore abrogated BCR-dependent secretion of T-cell chemokines (CCL3 and CCL4) by CLL cells [3]. |
| 體內活性 | Prophylactic treatment of mice with R406 administered 1 h before immune complex challenge reduced the cutaneous reverse passive Arthus reaction by approximately 72 and 86% at 1 and 5 mg/kg, respectively, compared with the vehicle control. The net optical density reading of extravasated dye extracted after treatment with R406 at 1 or 5 mg/kg R406 was reduced from 0.14 (vehicle) to 0.04 or 0.02, respectively. Treatment of injected C57BL/6 mice with 10 mg/kg R406 bid delayed the onset and reduced the severity of clinical arthritis. Paw thickening and clinical arthritis were reduced by approximately 50% [1]. R406 did not inhibit or delay the in vivo growth of solid tumors established from EBV-infected B cell lines. Instead, tumor growth in adjacent inguinal lymph nodes was observed exclusively in fostamatinib (R406 prodrug)-treated animals [2]. |
| 存儲條件 | Keep away from moisture,Store under nitrogen,
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | Ethanol : 8 mg/mL (12.73 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (6.36 mM), Sonication is recommended.
DMSO : 100 mg/mL (159.08 mM), Sonication is recommended.
|
| 關鍵字 | Syk | R-406 | R406 | R 406 | FLT3 | Apoptosis |
| 相關產(chǎn)品 | Urea | Formamide | Dimethyl phthalate | Aceglutamide | Alginic acid | Dextran sulfate sodium salt (MW 5000) | Metronidazole | Sildenafil citrate | Citric Acid Triammonium | Stavudine | Tamoxifen | Adenosine |
| 相關庫 | 抑制劑庫 | 血管生成庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 細胞凋亡化合物庫 | NO PAINS 化合物庫 | 血液病分子庫 | 膜蛋白靶向化合物庫 | 免疫/炎癥分子化合物庫 | 酪氨酸激酶分子庫 | 表型篩選靶點鑒定庫 |